Identification of New Anti‐ Trypanosoma brucei Leads: An Integrated CRK12 ‐Guided Virtual Screen With Experimental Validation
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70389 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2026. Written by Qin Li and 11 co-authors. Institution: Faculty of Applied Sciences, Macao Polytechnic University, Macao SAR, China. Major MEDLINE topics: Trypanosoma brucei brucei, Trypanocidal Agents, Protozoan Proteins, Protein Kinase Inhibitors. 44 references. The full text is freely available (open access, CC BY 4.0). Funded by: Macao Science and Technology Development Fund, National Natural Science Foundation of China, Fundo para o Desenvolvimento das Ciências e da Tecnologia.
Abstract (original language)
Human African trypanosomiasis (HAT), caused by Trypanosoma brucei , remains a neglected tropical disease with a critical shortage of therapeutic options, underscoring the need for new chemotypes. Cell division cycle‐2‐related kinase 12 (CRK12) has emerged as a genetically essential and chemically validated target in kinetoplastids, yet experimentally supported CRK12‐targeting chemotypes against T. brucei remain limited, and no experimental CRK12 structure is available. Here, we developed an integrated computational‐experimental screening workflow to accelerate CRK12‐guided hit discovery, combining ligand‐based prescreening, structure‐based virtual screening, molecular dynamics (MD) refinement, and experimental validation. An 8.6‐million‐compound library was prescreened using MACCS fingerprint screening and complex‐based pharmacophore screening, followed by staged docking and MD simulations to prioritize candidates for experimental testing. Notably, four of ten purchased compounds showed strong growth inhibition against T. brucei at 10 μM, with IC 50 values of 6.09, 1.47, 0.81, and 1.33 μM, demonstrating a promising hit rate for this data‐limited target. Binding‐mode analysis revealed a conserved hinge‐anchoring interaction pattern in the ATP‐binding pocket, providing a structural rationale for follow‐up analogue design. Overall, this study identifies new chemical starting points for anti‐ T. brucei drug discovery and demonstrates the utility of an AlphaFold2‐enabled CRK12‐guided screening strategy for targets with limited structural and ligand data.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Faculty of Applied Sciences, Macao Polytechnic University, Macao SAR, China.
- MOE Key Laboratory of Gene Function and Regulation, State Key Laboratory of Biocontrol and Guangdong Provincial Key Laboratory of Aquatic Economic Animals, School of Life Sciences, Sun Yat-Sen University, Guangzhou, Chi…
ORCID profiles: Jiayi Luo, Qianqian Zhang, Jiayue Qiu, Henry H Y Tong, Xiaojun Yao, Dehua Lai, Huanxiang Liu
Funding
- Macao Science and Technology Development Fund
- National Natural Science Foundation of China
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
Cite
APA
Li, Q., Fu, C., Luo, J., Zhang, Q., Wang, L., Liu, X., Qiu, J., Gong, X., Tong, H. H. Y., Yao, X., Lai, D., & Liu, H. (2026). Identification of New Anti‐ Trypanosoma brucei Leads: An Integrated CRK12 ‐Guided Virtual Screen With Experimental Validation. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70389
Vancouver
Li Q, Fu C, Luo J, Zhang Q, Wang L, Liu X, et al. Identification of New Anti‐ Trypanosoma brucei Leads: An Integrated CRK12 ‐Guided Virtual Screen With Experimental Validation. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70389
BibTeX
@article{Li2026,
author = {Li, Qin and Fu, Chenggong and Luo, Jiayi and Zhang, Qianqian and Wang, Lingling and Liu, Xiaomeng and Qiu, Jiayue and Gong, Xiaoqing and Tong, Henry H Y and Yao, Xiaojun and Lai, Dehua and Liu, Huanxiang},
title = {Identification of New Anti‐ Trypanosoma brucei Leads: An Integrated CRK12 ‐Guided Virtual Screen With Experimental Validation},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70389}
}
EUVIMED